OncoMatch/Clinical Trials/NCT05194397
Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors
Is NCT05194397 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for lymphoblastic leukemia.
This will be a randomized, placebo-controlled trial with a 2x2 factorial design testing the effects of an NAD+ precursor (NR) and exercise on skeletal muscle quality and VO2max in AYA HCT survivors. The primary outcome is the change in muscle strength (isometric knee extension) from baseline to 16 weeks. Key secondary outcomes are the change in muscle strength (ankle plantarflexion) from baseline to 16 weeks, the change in grip strength from baseline to 16 weeks, the change in lower extremity muscle mass from baseline to 16 weeks, the change in muscle OXPHOS capacity from baseline to 16 weeks, and the change in aerobic capacity (VO2 max) from baseline to 16 weeks.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Myelodysplastic Syndrome
Acute Myeloid Leukemia
Prior therapy
Must have received: stem cell transplant — allogeneic
Lab requirements
Blood counts
Hemoglobin ≥ 10 g/dL; Platelets ≥ 50,000
Kidney function
eGFR ≥ 60 ml/min/1.73 m2
Liver function
ALT/AST ≤ 3 x ULN
Hemoglobin < 10 g/dL; Platelets < 50K; Kidney disease (eGFR < 60 ml/min/1.73 m2); Liver disease Alanine aminotransferase (ALT)/Aspartate aminotransferase (AST) (ALT/AST > 3 x ULN)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Medical Center · Duarte, California
- Children's Hospital of Philadelphia · Philadelphia, Pennsylvania
- St. Jude Children's Research Hospital · Memphis, Tennessee
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify